Morrison Foerster advised Augmedix, a leader in ambient AI medical documentation and data solutions, in connection to its definitive agreement to be acquired by Commure, Inc. (“Commure”), a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value.
Under the terms of the agreement with Augmedix, Commure will acquire all outstanding shares of Augmedix common stock for a total equity value of approximately $139 million. Augmedix stockholders will receive $2.35 in cash per share. Augmedix’s Board of Directors unanimously approved the transaction. The closing of the transaction is expected in late Q3 or early Q4, subject to approval by Augmedix stockholders and the satisfaction of other customary closing conditions. Upon completion of the transaction, Augmedix’s common stock will no longer be publicly listed, and Augmedix will become a privately held company.
The MoFo team was led by San Francisco corporate partners John Rafferty and Michael O’Bryan, with support from San Francisco corporate associates Ken Taylor, Daigo Takahashi and Andrew Freiwald.
Read the press release.
